Cinqair (reslizumab)

For adjunctive maintenance therapy of severe eosinophilic asthma in adults, the recommended dosage of reslizumab is 3 mg/kg IV every 4 weeks.

Reslizumab is administered by IV infusion. The drug must not be administered by rapid IV injection (e.g., IV push or bolus).

Reslizumab injection concentrate must be diluted prior to administration.

Diluted reslizumab solution should be administered in a healthcare setting by a clinician who is prepared to manage anaphylaxis. If the diluted solution is refrigerated, it should reach room temperature prior to administration. An infusion set with a compatible, low-protein-binding 0.2-microm inline filter should be used (e.g., polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, cellulose acetate inline infusion filter).

Diluted reslizumab solution should be administered by IV infusion over 20-50 minutes; infusion time may vary depending on the total volume of the solution based upon the patient's weight. To ensure that the entire dose of reslizumab has been administered, the IV administration set should be flushed with 0.9% sodium chloride injection after IV infusion of the drug is complete. The patient should be observed during the infusion and for an appropriate period of time following the infusion.

Reslizumab infusion should be immediately discontinued if the patient experiences a severe systemic reaction, including anaphylaxis. (See Sensitivity Reactions under Cautions: Warnings/Precautions.)

Diluted reslizumab solution should not be administered in the same IV line with any other drug. To date, no physical or biochemical compatibility studies with other drugs have been conducted.

Unopened vials containing reslizumab injection concentrate should be stored at 2-8degreesC in the original package, protected from light, and should not be shaken or frozen.

No dosing information is available for this tab.

Specific drug interaction studies have not been conducted to date with reslizumab.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Igg Antibodies And Derivatives/Efgartigimod-Alfa

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)

Igg Antibodies And Derivatives/Nipocalimab-Aahu

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Igg Antibodies And Derivatives/Rozanolixizumab-Noli

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)

DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)

Reslizumab is contraindicated in patients with a history of hypersensitivity to the drug or any ingredient in the formulation.

• Acute asthma attack

• Parasitic infection

There are no moderate contraindications for this drug.

Adverse effects reported in at least 2% of patients receiving reslizumab and at an incidence higher than that reported with placebo include headache, upper respiratory tract infection, allergic rhinitis, back pain, sinusitis, urinary tract infection, dyspnea, dizziness, oropharyngeal pain, nausea, and vomiting.

Rare or Very Rare

• Anaphylaxis
• Malignancy

More Frequent

• Increased creatine kinase level
• Sore throat

Less Frequent

• Fatigue
• Muscle spasm
• Musculoskeletal pain
• Myalgia
• Neck pain
• Non-cardiac chest pain

No enhanced messaging available.

Safety and efficacy of reslizumab in pediatric patients younger than 18 years of age have not been established.

Monoclonal antibodies, such as reslizumab, are transported across the placenta in a linear fashion as pregnancy progresses with potential effects on the fetus being more likely during the second and third trimesters. However, there was no evidence of fetal harm in mice and rabbits following administration of reslizumab during organogenesis at dosages producing exposures up to 17 times the exposure at the maximum recommended human dosage.

It is not known whether reslizumab is distributed into human milk. However, the drug is distributed into the milk of lactating mice. Since human IgG is distributed into milk in humans, reslizumab is expected to distribute into human milk. The potential risks of infant exposure to reslizumab should be weighed against the mother's clinical need for the drug as well as the known benefits of breast-feeding.

In clinical trials, no overall differences in efficacy or safety were observed in patients 65 years of age or older when compared with younger patients.